Related Experiment Videos
Intraperitoneal therapy in ovarian cancer: time's not up
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.
Annals of oncology : official journal of the European Society for Medical Oncology·2013
Non-steroidal anti-inflammatory drugs, acetaminophen, and risk of skin cancer in the Nurses' Health Study.
Cancer causes & control : CCC·2012
Global acetylation and methylation changes predict papillary urothelial neoplasia of low malignant potential recurrence: a quantitative analysis.
International journal of immunopathology and pharmacology·2011
A meta-analysis of the efficacy of intraperitoneal cisplatin for the front-line treatment of ovarian cancer.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007
Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2007
Molecularly Guided Therapy Versus Continued Chemotherapy in Unfavorable Cancer of Unknown Primary: Updated Efficacy and Safety From the Randomized, Phase II CUPISCO Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Long-Term Survival Outcomes of Modified-FOLFOXIRI Plus Cetuximab Versus Bevacizumab in RAS/BRAF Wild-Type Metastatic Colorectal Cancer: Final Analysis of the DEEPER Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Refined Continuous Risk Index for Accurately Predicting Outcomes of Patients With Chronic Lymphocytic Leukemia After Limited-Duration Therapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Medical Therapy for Hormone Receptor-Positive, HER2-Negative Stage I-III Breast Cancer: ASCO Living Guideline, Version 2026.1.0.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: A Phase III Randomized Clinical Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026